|
31/03/2025
|
07:00
|
Interim Results for six months ended 31 Dec 2024
|
RNS
|
|
27/03/2025
|
07:00
|
Advancement to final phase of PROTECT trial
|
RNS
|
|
03/03/2025
|
07:00
|
New Executive Long Term Incentive Awards
|
RNS
|
|
27/02/2025
|
07:00
|
Presentations at 2025 AAAAI / WAO Joint Congress
|
RNS
|
|
17/02/2025
|
07:00
|
Grass MATA MPL Phase III data published in Allergy
|
RNS
|
|
14/02/2025
|
07:00
|
Grant of Options
|
RNS
|
|
28/01/2025
|
07:00
|
Half Year Trading update
|
RNS
|
|
22/01/2025
|
07:00
|
PDMR Dealing and Total Voting Rights
|
RNS
|
|
15/01/2025
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
|
19/12/2024
|
13:41
|
Exercise of Options and Total Voting Rights
|
RNS
|
|
17/12/2024
|
16:19
|
Block Listing Interim Review
|
RNS
|
|
16/12/2024
|
15:33
|
Result of Annual General Meeting
|
RNS
|
|
04/12/2024
|
07:00
|
Positive Interim Data from PROTECT Trial
|
RNS
|
|
27/11/2024
|
07:00
|
First Patient Dosed in G308 Paediatric Trial
|
RNS
|
|
25/11/2024
|
07:00
|
Submission of MAA for Grass MATA MPL
|
RNS
|
|
21/11/2024
|
07:00
|
Notice of 2024 Annual General Meeting
|
RNS
|
|
06/11/2024
|
07:00
|
Audited Preliminary Results 2024
|
RNS
|
|
21/10/2024
|
07:00
|
Commencement of Phase III Paediatric Trial
|
RNS
|
|
16/10/2024
|
07:00
|
Update on funding
|
RNS
|
|
01/10/2024
|
07:00
|
Update on funding and preliminary results
|
RNS
|
|
17/09/2024
|
07:00
|
Progression of patient cohorts in PROTECT Trial
|
RNS
|
|
27/08/2024
|
07:00
|
Update on funding
|
RNS
|
|
22/07/2024
|
07:00
|
Appointment of Nominated Adviser and Sole Broker
|
RNS
|
|
22/07/2024
|
07:01
|
Trading update for the year ended 30 June 2024
|
RNS
|
|
04/07/2024
|
14:22
|
Launch of new Company Long Term Incentive Plan
|
RNS
|
|
27/06/2024
|
07:00
|
Appointment of Non-Executive Director
|
RNS
|
|
10/06/2024
|
07:00
|
Progression of patient cohorts in PROTECT Trial
|
RNS
|
|
03/06/2024
|
07:00
|
Successful meetings with Paul Ehrlich Institut
|
RNS
|
|
07/05/2024
|
07:00
|
Further detail from G306 Phase III field trial
|
RNS
|
|
03/04/2024
|
07:00
|
Director Resignation
|
RNS
|
|
27/03/2024
|
07:00
|
Update on funding
|
RNS
|
|
27/03/2024
|
07:00
|
Interim Results for six months ended 31 Dec 2023
|
RNS
|
|
12/03/2024
|
08:59
|
VLP Peanut PROTECT Trial Update
|
RNS
|
|
11/03/2024
|
07:00
|
Appointment of Shaun Furlong to Board of Directors
|
RNS
|
|
08/03/2024
|
13:49
|
Result of AGM
|
RNS
|
|
14/02/2024
|
07:00
|
Half-Year Trading Update 2024
|
RNS
|
|
09/02/2024
|
15:07
|
Notice of 2023 Annual General Meeting
|
RNS
|
|
30/01/2024
|
07:30
|
Restoration - Allergy Therapeutics plc
|
RNS
|
|
30/01/2024
|
07:00
|
Publication of Annual Report and Accounts 2023
|
RNS
|
|
04/01/2024
|
12:29
|
Total Voting Rights
|
RNS
|
|
02/01/2024
|
07:30
|
Suspension - Allergy Therapeutics plc
|
RNS
|
|
27/12/2023
|
12:01
|
Amendment to existing Facility Agreement
|
RNS
|
|
15/12/2023
|
12:48
|
Annual Report and Accounts Delayed
|
RNS
|
|
13/12/2023
|
16:54
|
PDMR dealing and Total Voting Rights
|
RNS
|
|
13/12/2023
|
07:00
|
G306 Phase III trial meets key endpoints
|
RNS
|
|
11/12/2023
|
07:00
|
Update on funding
|
RNS
|
|
01/12/2023
|
07:00
|
Total Voting Rights
|
RNS
|
|
28/11/2023
|
15:03
|
Holding(s) in Company
|
RNS
|
|
14/11/2023
|
07:00
|
G306 Grass Phase III trial meets primary endpoint
|
RNS
|
|
10/11/2023
|
14:39
|
Form 8.5 (EPT/RI)
|
RNS
|